MET exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features

被引：0
|
作者：
Yuan, Lisi [1 ]
Bosler, David [2 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Cleveland Clin, Beachwood, OH USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1974
引用
收藏
页码：1831 / 1832
页数：2
相关论文
共 50 条
  • [31] Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer
    Minne, Rachel L.
    Luo, Natalie Y.
    Traynor, Anne M.
    Huang, Minxuan
    Detullio, Luisina
    Godden, Jen
    Stoppler, Melissa
    Kimple, Randall J.
    Baschnagel, Andrew M.
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [32] Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations
    Yamaguchi, Miki
    Hirai, Sachie
    Idogawa, Masashi
    Uchida, Hiroaki
    Sakuma, Yuji
    EXPERIMENTAL CELL RESEARCH, 2022, 413 (02)
  • [33] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [34] MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Aguado, Cristina
    Rodriguez, Sonia
    Bertran-Alamillo, Jordi
    Castellvi, Josep
    Yeste, Zaira
    Perez, Ana
    Rosell, Rafael
    Molina-Vila, Miguel Angel
    CANCER RESEARCH, 2017, 77
  • [35] Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer
    Recondo, G., Jr.
    Bahcall, M.
    Sholl, L.
    Leonardi, G.
    Ricciuti, B.
    Nguyen, T.
    Venkatraman, D.
    Lamberti, G.
    Umeton, R.
    Janne, P.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S285 - S285
  • [36] Expression of stem cell markers in non-small cell lung carcinoma (NSCLC) and correlation with clinicopathologic features
    Yuan Ping
    Behrens, Carmen
    Huang Jiaoti
    Spinola, Monica
    Prudkin, Ludmila
    Dong Wenli
    Yin Guosheng
    Moran, Cesar A.
    Kim, Edward S.
    Zhou Bin-Bing
    Minna, Jonh D.
    Wistuba, Ignacio I.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S406 - S406
  • [37] Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective
    Subramanian, Janakiraman
    Tawfik, Ossama
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 877 - 886
  • [38] Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
    Hur, Joon Young
    Ku, Bo Mi
    Shim, Joon Ho
    Jung, Hyun Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    IN VIVO, 2020, 34 (03): : 1399 - 1406
  • [39] The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation
    Rocco, Danilo
    Della Gravara, Luigi
    Palazzolo, Giovanni
    Gridelli, Cesare
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (21) : 3043 - 3056
  • [40] Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
    Hong, Lingzhi
    Zhang, Jianjun
    Heymach, John, V
    Le, Xiuning
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345